Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Nadim Ahmed
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 109
- Beta
- -0.01
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 9.19
Financials
Revenue
$0.00-100.0%Net Income
$-53.70MEBITDA
$-53.63MFree Cash Flow
$-38.22MEPS (diluted)
$-0.81Shares Outstanding (diluted)
61.49M+7586.3%Operating Expenses
$57.25MCash & Debt
$334.54MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-219.88M | $-3.72 |
| 2024 | $0.00 | $-167.38M | $-3.11 |
| 2023 | $0.00 | $-153.16M | $-3.69 |
| 2022 | $0.00 | $111.21M | $2.46 |
| 2021 | $18.94M | $-65.57M | $-1.48 |
| 2020 | $0.00 | $-51.80M | $-1.19 |
| 2019 | $0.00 | $-20.04M | $-19.70 |
| 2018 | $0.00 | $-14.19M | $-17.74 |
Valuation
CGEMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
33+11.11%Social Signal Score
Mentions (12)
- Newsglobenewswire.com·4d ago·Negative
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC
View source ↗ - Newsseekingalpha.com·7d ago·Neutral
…g Pullback For CLN-978's Potential In Autoimmune Diseases I think Cullinan Therapeutics' recent pullback is a compelling price entry ahead of their clinical updates. CGEM has scheduled updates for its autoimmune pipeline for December 2026. The combined CLN-978 results could help corroborate its earlier data. Additionally, if CLN-978 becomes viable for more patients with a manageable safety profile, the potential repeat dosing also seems promising for better efficacy.
View source ↗ - Newsmarketbeat.com·8d ago·Neutral
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049 Cullinan Therapeutics NASDAQ: CGEM outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978 and data presentations for other programs in November and the fourth quarter.
View source ↗ - Newsglobenewswire.com·12d ago·Positive
… (FLT3 TCE) updated data from the Phase 1 dose escalation study in December CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today outlined fourth quarter 2026 milestones across its immunology and oncology pipeline.
View source ↗ - Newsglobenewswire.com·14d ago·Positive
…to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at t…
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript
View source ↗ - Newsglobenewswire.com·22d ago·Positive
…REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m.
View source ↗ - Newsgurufocus.com·22d ago·Neutral
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial e
View source ↗ - Newsbusinesswire.com·22d ago·Neutral
…ng Cancer PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation-positive non-small cell lung cancer (NSCLC). The data were presented at the Inte…
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, September 13, 2026
View source ↗ - Newsseekingalpha.com·41d ago·Neutral
…s, reducing reliance on external funding. Zipalertinib's positive Phase 3 results and upcoming regulatory milestones provide a potential funding bridge for advancing CGEM's autoimmune and oncology platforms. CLN-049's accelerated regulatory path in AML and CLN-978's promising early autoimmune data position CGEM for multiple commercialization opportunities.
View source ↗ - Newsbenzinga.com·53d ago·Negative
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape Taiho Oncology Inc., Taiho Pharmaceutical Co. Ltd., and Cullinan Therapeutics Inc. (NASDAQ:CGEM) on Thursday shared data from their global REZILIENT3 Phase 3 trial of zipalertinib in certain lung cancer patients.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.84 per share
Typical surprise +3.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.81 vs $-0.80miss
- Thu, May 7$-0.75 vs $-0.84beat
- Tue, Mar 10$-0.77 vs $-0.80beat
- Thu, Nov 6$-0.77 vs $-0.95beat
- Thu, Aug 7$-1.07 vs $-0.83miss
- Thu, May 8$-0.74 vs $-0.78beat
Estimates and results for CGEM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CGEM officers and directors.
- Bought
- $13.3m
- Sold
- $3.3m
8 trades
40 trades
- Michaelson Jennifersold
- Michaelson Jennifersold
- Michaelson Jennifersold
- Michaelson Jennifersold
- Michaelson Jennifersold
- Michaelson Jennifersold
- Michaelson Jennifersold
- Michaelson Jennifersold
52 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CGEM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.